Cite
Klaska IP, White A, Villacampa P, et al. Intravitreal administration of recombinant human opticin protects against hyperoxia-induced pre-retinal neovascularization. Exp Eye Res. 2021;108908doi: 10.1016/j.exer.2021.108908.
Klaska, I. P., White, A., Villacampa, P., Hoke, J., Hervás, L. A., Maswood, R. N., Ali, R. R., Bunce, C., Unwin, R. D., Cooper, G. J. S., Bishop, P. N., & Bainbridge, J. W. (2021). Intravitreal administration of recombinant human opticin protects against hyperoxia-induced pre-retinal neovascularization. Experimental eye research, 108908. https://doi.org/10.1016/j.exer.2021.108908
Klaska, Izabela P, et al. "Intravitreal administration of recombinant human opticin protects against hyperoxia-induced pre-retinal neovascularization." Experimental eye research vol. (2021): 108908. doi: https://doi.org/10.1016/j.exer.2021.108908
Klaska IP, White A, Villacampa P, Hoke J, Hervás LA, Maswood RN, Ali RR, Bunce C, Unwin RD, Cooper GJS, Bishop PN, Bainbridge JW. Intravitreal administration of recombinant human opticin protects against hyperoxia-induced pre-retinal neovascularization. Exp Eye Res. 2021 Dec 23;108908. doi: 10.1016/j.exer.2021.108908. Epub 2021 Dec 23. PMID: 34954204.
Copy
Download .nbib